Q-omics provides the consensus-scored HSPBP1 profile across patient tissues and cancer cell-line models. HSPBP1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, HSPBP1 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, HSPBP1 protein abundance shows 29,658 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, COAD, and LSCC as cancer lineages where HSPBP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSPBP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSPBP1 survival associations across molecular data types. HSPBP1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSPBP1 RNA expression–survival associations across cancer types. High HSPBP1 expression shows unfavorable associations in ACC, MESO, LIHC, LUAD and LGG, but favorable associations in SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for HSPBP1 RNA expression.
This table summarizes HSPBP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRP for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for HSPBP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSPBP1 shows higher tumor expression in COAD, KIRP, LIHC, STAD, HNSC and BLCA. The COAD box plot shows higher HSPBP1 RNA expression in tumor versus normal tissue (log2 FC = +1.272, t-test p < 0.001).
This table shows molecular features associated with HSPBP1 in patient tissues and cancer cell lines. In patient samples, HSPBP1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, HSPBP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Lymphoma.
